Unknown

Dataset Information

0

Rotigaptide protects the myocardium and arterial vasculature from ischaemia reperfusion injury.


ABSTRACT: AIM:Ischaemia-reperfusion injury (IRI) causes impaired endothelial function and is a major component of the adverse effects of reperfusion following myocardial infarction. Rotigaptide increases gap junction conductance via connexin-43. We tested the hypothesis that rotigaptide reduces experimental myocardial infarction size and ameliorates endothelial IRI in humans. METHODS:Myocardial infarction study: porcine myocardial infarction was achieved by catheter-induced occlusion of the left anterior descending artery. In a randomized double-blind study, rotigaptide (n = 9) or placebo (n = 10) was administered intravenously as a 10 min bolus prior to reperfusion and continuously during 2 h of reperfusion. Myocardial infarction size (IS) was assessed as proportion of the area at risk (AAR). Human translational study: forearm IRI was induced in the presence or absence of intra-arterial rotigaptide. In a randomized double-blind study, forearm arterial blood flow was measured at rest and during intra-arterial infusion of acetylcholine (5-20 ?g min(-1) ; n = 11) or sodium nitroprusside (2-8 mg min(-1) ; n = 10) before and after intra-arterial infusion of placebo or rotigaptide, and again following IRI. RESULTS:Myocardial infarction study: Rotigaptide treatment was associated with a reduction of infarct size (IS/AAR[%]: 18.7 ± 4.1 [rotigaptide] vs. 43.6 ± 4.2 [placebo], P = 0.006). Human translational study: Endothelium-dependent vasodilatation to acetylcholine was attenuated after ischaemia-reperfusion in the presence of placebo (P = 0.007), but not in the presence of rotigaptide (P = NS). Endothelium-independent vasodilatation evoked by sodium nitroprusside was unaffected by IRI or rotigaptide (P = NS). CONCLUSIONS:Rotigaptide reduces myocardial infarction size in a porcine model and protects from IRI-related endothelial dysfunction in man. Rotigaptide may have therapeutic potential in the treatment of myocardial infarction.

SUBMITTER: Pedersen CM 

PROVIDER: S-EPMC4876181 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Rotigaptide protects the myocardium and arterial vasculature from ischaemia reperfusion injury.

Pedersen Christian M CM   Venkatasubramanian Sowmya S   Vase Henrik H   Hyldebrandt Janus A JA   Contractor Hussain H   Schmidt Michael R MR   Bøtker Hans Erik HE   Cruden Nicholas L NL   Newby David E DE   Kharbanda Rajesh K RK   Lang Ninian N NN  

British journal of clinical pharmacology 20160310 6


<h4>Aim</h4>Ischaemia-reperfusion injury (IRI) causes impaired endothelial function and is a major component of the adverse effects of reperfusion following myocardial infarction. Rotigaptide increases gap junction conductance via connexin-43. We tested the hypothesis that rotigaptide reduces experimental myocardial infarction size and ameliorates endothelial IRI in humans.<h4>Methods</h4>Myocardial infarction study: porcine myocardial infarction was achieved by catheter-induced occlusion of the  ...[more]

Similar Datasets

| S-EPMC5909650 | biostudies-literature
| S-EPMC8786462 | biostudies-literature
| S-EPMC6404100 | biostudies-literature
| S-EPMC548534 | biostudies-literature
| S-EPMC8787978 | biostudies-literature
| S-EPMC7460692 | biostudies-literature